Overview

Regeneron Pharmaceuticals Inc. is a biopharmaceutical company that discovers, develops and intends to commercialize therapeutic drugs for the treatment of serious medical conditions. Regeneron’s focus has expanded to include programs to develop therapeutics for the treatment of obesity, rheumatoid arthritis, cancer, allergies, asthma and ischemia. Founded in 1988, its initial thrust was toward degenerative neurological disease therapeutics. Other early stage programs are in the areas of fibrosis and G protein-coupled receptors.

The Targeted Genomic and Functionomics technology platforms discover specific genes of therapeutic interest for a particular disease or cell type. Regeneron also uses its Designer Protein Therapeutics platform to genetically engineer product candidates. Using these technologies, the company has discovered new families of growth factors and receptors, which have led to multiple product candidates.

It has several drug candidates in clinical trials, as well as several product candidates that are expected to enter clinical trials over the next two years. Products include Axokine, an anti-obesity drug intended to regulate dietary intake and energy expenditure; the IL-1 Trap for rheumatoid arthritis; the VEGF Trap, a vascular endothelial growth factor antagonist, and its angiopoietins, a family of growth factors specific to blood vessels and early hemopoietic stem cells; and neurotrophin-3, a naturally occurring human protein for treatment of functional constipation.

Partners

Regeneron is conducting research with the Procter & Gamble Co. in muscle diseases and other fields. Regeneron also is collaborating with Medarex Inc. to discover, develop and commercialize certain human antibodies as therapeutics. In a partnership with Amgen Inc., Regeneron is conducting clinical trials with neurotrophin-3 for the treatment of constipation conditions. Shearwater Corp. will use its PEGylation technology to develop a PEGylated form of Axokine.